KALA BIO Delivers Industry-Leading AI Infrastructure: Bionic Intelligence Research Agent Now Live

Rhea-AI Summary

KALA BIO (NASDAQ: KALA) announced the commercial launch of the Bionic Intelligence Research Agent (BIRA) on March 30, 2026, delivered via the Researgency.ai platform under an exclusive worldwide license with Younet. BIRA runs a 70-billion-parameter model for biotech and pharma research inside VPN-only, client-controlled infrastructure.

The platform targets enterprise security, audit trails, private data sovereignty, and a platform-as-a-service revenue model, and Kala highlighted a near-term roadmap of four agentic features including alerts, IP monitoring, and compressed publication reviews.

Positive

• Commercial deployment of BIRA on March 30, 2026
• Exclusive worldwide license with Younet for Researgency.ai
• On-premises, VPN-only deployment ensuring data sovereignty
• Platform designed to support PaaS recurring revenue

Negative

• No disclosed customer counts, contract values, or revenue from the deployment
• Company warns no assurance it will capture market share or generate substantial recurring revenue

Key Figures

Researgent model size: 70 billion parameters New AI capabilities: 4 features Deployment commitment: 14 days +5 more

8 metrics

Researgent model size 70 billion parameters Researgent 2.0 large language model powering BIRA

New AI capabilities 4 features Four additional agentic AI capabilities in active development

Deployment commitment 14 days Timeline previously communicated for first AI agent shipment

Market capitalization $182,266,045 Pre-news market cap from market context

Resale registration shares 241,435,910 shares Shares registered for resale under S-3/424B3

Outstanding shares 911,330,225 shares Common shares outstanding as of February 4, 2026

Younet share payment 5,000,000 shares Common stock to be issued to Younet in initial license term

Younet acquisition option $55,000,000 Option price to acquire all of Younet’s equity or assets

Market Reality Check

Price: $0.1757 Vol: Volume 4,352,230 is 0.23x...

low vol

$0.1757 Last Close

Volume Volume 4,352,230 is 0.23x the 20-day average of 18,689,002, suggesting muted trading interest pre-news. low

Technical Shares at 0.1757 are trading below the 200-day MA of 3.87 and sit close to the 52-week low of 0.1607, far from the 20.6 high.

Peers on Argus

KALA was down 12.15% while peers showed mixed weakness: names like CRBP, TARA, B...

KALA was down 12.15% while peers showed mixed weakness: names like CRBP, TARA, BMEA, and EQ fell between roughly -2.94% and -9.18%, with IKT up 1.82%. No momentum peers or common same-day headlines were flagged, pointing to stock-specific dynamics rather than a coordinated AI/biotech move.

Previous AI Reports

2 past events · Latest: Mar 11 (Positive)

Same Type Pattern 2 events

Date	Event	Sentiment	Move	Catalyst
Mar 11	AI agent launch	Positive	+24.2%	Promised first commercial AI agent shipment within 14 days and platform rebrand.
Mar 04	AI strategy deal	Positive	-1.5%	Announced strategic AI initiative and exclusive Researgency license for biotech clients.

Pattern Detected

Recent AI-tagged news often drew strong reactions, with one sizeable gain and one mild decline, indicating mixed but sometimes pronounced sensitivity to AI milestones.

Recent Company History

Over the past month, KALA has steadily built its AI story. On Mar 4, it announced a strategic initiative and exclusive license for the Researgency platform, with shares dipping slightly. On Mar 11, it highlighted rebranding to Researgency.ai and promised its first agent shipment within 14 days, which coincided with a 24.16% gain. Today’s BIRA go-live advances that roadmap from planned deployment to active enterprise use.

Historical Comparison

+11.3% avg move · KALA’s prior AI-tagged releases moved an average of 11.31%, ranging from a modest decline to a 24.16...

AI

+11.3%

Average Historical Move AI

KALA’s prior AI-tagged releases moved an average of 11.31%, ranging from a modest decline to a 24.16% gain. This live deployment continues the AI build-out but follows two earlier strategy and launch updates in quick succession.

Recent AI news shows a clear progression: initial strategic licensing and platform vision on Mar 4, commitment to ship the first agent within 14 days on Mar 11, and now full commercial deployment of the Bionic Intelligence Research Agent for enterprise use.

Regulatory & Risk Context

Active S-3 Shelf

Shelf Active

Active S-3 Shelf Registration 2026-02-09

An effective S-3 resale registration covers up to 241,435,910 existing-shareholder shares, including 238,335,910 from preferred conversions, 2,200,000 to LifeSci Capital, and 900,000 settlement shares for Baker Brothers. KALA receives no proceeds from these sales but bears registration costs, while the filing and related disclosures highlight existing Nasdaq listing-deficiency risks around market value and minimum bid price.

Market Pulse Summary

This announcement moves KALA from AI strategy to execution, with the Bionic Intelligence Research Ag...

Analysis

This announcement moves KALA from AI strategy to execution, with the Bionic Intelligence Research Agent now live on secure, on-premises infrastructure and powered by a 70-billion-parameter model. It extends a sequence of AI-focused updates in March and builds on the exclusive Researgency license. Investors may monitor adoption levels, recurring platform-as-a-service traction, and how these efforts interact with existing resale registrations and Nasdaq compliance milestones disclosed in recent filings.

Key Terms

agentic ai, large language model, platform-as-a-service, text-to-speech

4 terms

agentic ai technical

"the Company's first purpose-built agentic AI solution delivered through its Researgency.ai platform"

Agentic AI refers to computer systems that can make their own decisions and take actions without needing someone to tell them what to do each time. It's like giving a robot a degree of independence to solve problems or achieve goals on its own, which matters because it could change how we work and interact with technology in everyday life.

large language model technical

"Researgent 2.0, a 70-billion-parameter large language model trained on vast datasets"

A large language model is a computer system trained on vast amounts of text to understand and generate human-like writing, like a very well-read virtual assistant that can summarize, draft, translate, or answer questions. Investors care because it can change how businesses operate and compete—boosting productivity, cutting costs, or enabling new products—while also creating risks around accuracy, regulation, and security that can affect revenue and valuation.

platform-as-a-service financial

"support a platform-as-a-service model for recurring revenue, and enable swift deployment"

A platform-as-a-service is a cloud-based product that provides developers with ready-made tools, computing power and storage to build, run and manage software without owning the underlying hardware or plumbing. Think of it like renting a fully equipped kitchen to prepare meals instead of buying appliances and renovating a home. For investors, it matters because these platforms often generate steady, repeatable revenue, scale efficiently as users grow, and can create customer stickiness that supports long-term margins and valuation.

text-to-speech technical

"This automation solution includes text-to-speech for hands-free consumption"

Text-to-speech is software that converts written words into natural-sounding spoken audio, like a narrator reading a page aloud. For investors it matters because it can broaden a product’s audience (for example, people who prefer audio or need accessibility), reduce customer support and content production costs, and create new revenue or engagement channels—factors that can affect user growth, margins, and regulatory compliance.

AI-generated analysis. Not financial advice.

Next-Generation Agentic AI Platform Achieves Live Enterprise Deployment, Delivering Secure, Scalable, Autonomous Research Solutions to Global Biotechnology and Pharmaceutical Organizations

ARLINGTON, Mass., March 30, 2026 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ: KALA) (“Kala” or the “Company”) today announced the initial commercial deployment of the Bionic Intelligence Research Agent (BIRA), the Company's first purpose-built agentic AI solution delivered through its Researgency.ai platform (under exclusive worldwide license with Younet). This milestone marks Kala's transformation into an operational AI infrastructure partner for the global biotechnology industry.

The launch follows the Company's March 11 announcement that its first AI agent would ship within 14 days, a commitment Kala has met on schedule, demonstrating the Company's ability to execute on commitments and its readiness to deliver commercial-grade AI solutions at enterprise scale.

INDUSTRY-LEADING AI INFRASTRUCTURE FOR BIOTECH

The Bionic Intelligence Research Agent is a fully autonomous AI research specialist built for the biotechnology and pharmaceutical sectors. Powered by Researgent 2.0, a 70-billion-parameter large language model trained on vast datasets in the biotech, healthcare, and scientific research sectors, BIRA delivers next-generation performance within secure enterprise infrastructure.

“Two weeks ago, we told the market that the first agent ships in 14 days. Today, it's live and with the potential to generate huge value,” said Avi Minkowitz, CEO of Kala. “The Bionic Intelligence Research Agent is not a demo; it is a working, enterprise-grade product inside private infrastructure right now. Our focus on secure, scalable AI deployment positions Kala at the forefront of the agentic transformation reshaping biomedical research. The pace of AI advancement is evident. Our goal is to maintain timely progress as we work with Younet to build out the Researgency platform for market use, and we intend to keep setting and meeting targets as we advance toward full platform commercialization.”

SECURE, PRIVATE AI DEPLOYMENT

Unlike public AI platforms, BIRA operates solely within client-controlled, VPN-secured environments, guaranteeing full data sovereignty with no external access to proprietary research data; enterprise-grade security that complies with pharmaceutical R&D standards; complete audit trails for regulatory documentation; and real-time performance with minimal cloud latency.

CORE PLATFORM CAPABILITIES

Autonomous Research Execution: The platform delivers multi-step query decomposition and cross-source synthesis from scientific literature, clinical trial databases, patent repositories, and pharma intelligence feeds via advanced automation.

Comprehensive Database Connectivity: Pre-built connectors provide integration with scientific literature, clinical and regulatory databases, global IP resources, market intelligence, and business data through a single secure interface.

Private Infrastructure Deployment: VPN-only access ensures all queries, results, and derived intelligence remain within organizational boundaries, maintaining complete security throughout the research workflow.

Quality Assurance & Confidence Scoring: Automated source verification, reliability scoring of quantitative evidence, and explicit flagging of knowledge gaps ensure enterprise-grade performance for research teams.

Research-Ready Visualization: Interactive, customisable graphical presentations designed for R&D decision-making enable real-time analysis and reporting.

SCALABLE AI PLATFORM ARCHITECTURE

BIRA's architecture integrates smoothly with Younet's Researgency platform infrastructure, designed to scale with the complexity of client organisations, leverage existing enterprise infrastructure investments, support a platform-as-a-service model for recurring revenue, and enable swift deployment across multiple business units. This scalable approach ensures that organisations of any size can benefit from the platform's AI solutions without sacrificing security or performance.

NEAR-TERM PRODUCT ROADMAP: FOUR INNOVATIONS IN ACTIVE DEVELOPMENT

Building on BIRA's foundation, Younet's engineering team in collaboration with Kala is actively developing four additional capabilities for near-term release, each representing significant innovation in agentic AI for the life sciences sector:

Daily Compressed Publications Review

An automated, scheduling-driven research digest that delivers AI-compressed summaries of publications across user-defined therapeutic verticals, such as oncology, neurology, and immunology. This automation solution includes text-to-speech for hands-free consumption and uses machine-learning-based priority filtering to highlight the most impactful findings in real time.

Trigger-Defined Real-Time Alerts

A versatile event-monitoring system that supports keyword triggers, alerts for starting clinical trials, notifications for regulatory decisions, and complex logic conditions from multiple sources. Alerts are sent via email, dashboard, mobile, or voice, with ML-driven false-positive reduction to ensure enterprise-grade reliability and performance.

Real-Time IP Filings Monitoring

Continuous monitoring of global patent filings with competitor tracking, technology area analysis, citation review, white-space detection, and freedom-to-operate risk alerts. This platform capability provides biotech and pharma organizations a real-time advantage in IP strategy through seamless integration with existing research workflows.

Prospective Dormant IP Identification

An intelligence module that systematically detects lapsed or abandoned patents with revival potential, cross-checks with client internal research priorities, and produces prioritized strategic recommendations with risk-benefit analysis. This innovation unlocks hidden value in the global IP landscape while maintaining complete security of proprietary analysis.

“There have been breakthrough advances in KV caching, Google's TurboQuant, and MIT's ‘Attention Matching’, leading to substantially lower inference costs. This creates new efficiencies in large-scale AI deployment and explains the rapid adoption of agent orchestration frameworks such as OpenClaw and Claude Channels over the past few weeks. We are observing a paradigm shift in how enterprises will deploy autonomous AI systems. The convergence of these technical breakthroughs with our Researgency.ai platform confirms our strategic thesis: that agentic AI will fundamentally reshape biomedical research, and those who act first will lead the industry's next chapter,” said Avi Minkowitz, CEO of Kala.

STRATEGIC SIGNIFICANCE: FROM INNOVATION TO COMMERCIAL EXECUTION

The launch of BIRA marks a significant turning point for Kala Bio. The Company has transitioned from platform readiness and strategic announcements to live commercial deployment precisely within the timeframe it communicated to the market. With BIRA now commercially live, the Researgency.ai platform has moved from a strategic ambition to an active revenue-generating opportunity.

Key strategic milestones achieved include transitioning from platform readiness to live commercial deployment, deploying operational enterprise-grade AI infrastructure, implementing a scalable platform architecture, creating an active, revenue-generating opportunity, and establishing a full platform commercialization roadmap.

The Bionic Intelligence Research Agent integrates seamlessly with Younet's Researgency platform infrastructure and is designed to complement, not replace, existing multi-LLM research workflows. Its design scales with organisational complexity, leverages existing enterprise infrastructure investments, and supports a platform-as-a-service model aimed at generating recurring revenue.

MARKET OPPORTUNITY & COMPETITIVE POSITIONING

With thousands of biotech and pharma companies worldwide facing research bottlenecks, compliance challenges, and competitive intelligence issues, BIRA is positioned to tap into a significant market opportunity. The target market includes the global biotechnology and pharmaceutical sectors. The platform's main differentiation is its on-premises secure deployment model compared to public cloud AI options. Its core value proposition focuses on proprietary data control combined with enterprise-scale AI performance, while the revenue model is based on platform-as-a-service with scalable recurring income potential.

Kala is now an operational AI infrastructure partner to the global biotech industry, delivering industry-leading solutions that combine next-generation agentic capabilities with uncompromising security, though no assurance can be given that it will capture any specific portion of that market, or that its efforts in that market will generate substantial recurring revenue or be profitable.

ABOUT KALA BIO (NASDAQ: KALA)

KALA BIO, Inc. is a clinical-stage biopharmaceutical company building a dedicated, on-premises AI infrastructure platform for the biotechnology industry. The Company's dual strategy combines a proprietary biologics pipeline—including its mesenchymal stem cell secretome (MSC-S) platform and FDA Orphan Drug- and Fast Track-designated product candidates—with a scalable AI platform-as-a-service business designed to deploy secure, purpose-built AI solutions directly within biotech and pharmaceutical client environments.

Through its exclusive worldwide license for the Researgency AI research platform from Younet, Kala intends to serve as the dedicated AI infrastructure partner for the biotechnology industry, enabling organizations of all sizes to unlock the value of their proprietary biological data without surrendering control. Kala is advancing an agentic transformation strategy for biomedical organizations through Researgency.ai, a platform designed to enable scalable, governed deployment of AI agents across research, documentation, and operational workflows. The Company's focus on enterprise security, real-time performance, and seamless integration positions it at the forefront of innovation in the life sciences AI sector.

Kala believes the future of biomedical innovation is in agentic systems.

For more information, visit www.kalarx.com and www.Researgency.ai

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the Company's strategic initiative to build an AI infrastructure platform for the biotechnology industry, plans to develop and deploy the Researgency AI platform both internally and to external clients, expectations regarding the potential benefits of AI-driven analytical tools, plans to reassess historical datasets and identify new therapeutic indications, expectations regarding the AI drug discovery market and industry trends, expectations regarding the Company's ability to generate recurring platform revenue, plans regarding potential partnerships, client deployments, or technology licensing opportunities, expectations regarding the Company's competitive position and the differentiation of its on-premises deployment model, the potential exercise of development continuation or renewal options under the Agreement, and other statements that are not historical facts.

The Company used words like “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions to identify these forward-looking statements. These statements involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance, or achievements to be materially different from those expressed or implied by such statements. Important factors that could cause such differences include, but are not limited to: risks that AI technologies may not produce expected results in drug discovery or development; risks related to the development, deployment, and performance of the Researgency platform; risks that the Company may not successfully attract or retain external platform clients; risks that the platform-as-a-service business model may not generate anticipated revenues; risks that the Company's product candidates may not be successfully developed or commercialized; risks related to the Company's limited cash resources and ability to continue as a going concern; risks that the third-party information contained herein was not accurate at the time it was published and/or does not accurately predict the future; risks related to the Company's ability to raise future capital and the possibility that market conditions may limit the Company's ability to raise capital on favorable terms; risks related to the Company's ability to regain compliance with Nasdaq listing requirements; competition from larger, better-resourced companies including major technology and pharmaceutical companies; dependence on key personnel and third-party technology providers; the accuracy of third-party market forecasts and projections cited herein; risks that the Company may elect not to expand or continue its deployment of the Researgency platform beyond the initial term; risks that Younet may not perform its obligations under the Agreement; and other risks detailed in the “Risk Factors” section of the Company's Annual Report on Form 10-K as they may be revised in the Company's Quarterly Reports on Form 10-Q and Current Reports on Form 8-K and other filings with the Securities and Exchange Commission.

Forward-looking statements speak only as of the date of this release, and the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.

Contact:

Avi Minkowitz
Chief Executive Officer, KALA BIO, Inc.
am@kalarx.com
www.kalarx.com | www.Researgency.ai

FAQ

What did KALA announce about BIRA on March 30, 2026?

KALA announced the commercial launch of the Bionic Intelligence Research Agent (BIRA) on March 30, 2026. According to the company, BIRA is live on Researgency.ai under an exclusive license with Younet and runs a 70-billion-parameter model in client-controlled infrastructure.

How does KALA's BIRA protect proprietary research data (KALA)?

BIRA operates inside client-controlled, VPN-only environments to maintain data sovereignty and auditability. According to the company, this prevents external access, provides enterprise-grade security, and creates complete audit trails for regulatory documentation.

What core capabilities does BIRA offer for biotech and pharma teams (KALA)?

BIRA offers autonomous multi-step research execution, cross-source synthesis, quality scoring, and research-ready visualizations. According to the company, connectors link literature, clinical, patent, and market feeds within a single secure interface for enterprise workflows.

Will BIRA generate recurring revenue for KALA (KALA)?

Kala positions BIRA as a platform-as-a-service intended to produce recurring revenue, but revenue is not yet disclosed. According to the company, BIRA represents an active revenue-generating opportunity, though no assurance of market capture or profitability is given.

What near-term features is KALA developing for Researgency.ai (KALA)?

Kala and Younet are developing four near-term capabilities: compressed publication reviews, trigger-defined alerts, real-time IP filings monitoring, and dormant IP identification. According to the company, these features aim to enhance agentic workflows for life sciences research teams.

What model powers BIRA and how is performance described (KALA)?

BIRA is powered by Researgent 2.0, described as a 70-billion-parameter large language model trained on biotech and scientific datasets. According to the company, the model delivers enterprise-grade, low-latency performance inside private infrastructure.